Zobrazeno 1 - 10
of 182
pro vyhledávání: '"Tryfonopoulos D"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Lichenoid granulomatous reactions (LGR) are granulomatous inflammations of the skin and oral mucosa, also sharing features of lichenoid lesions. Thus, the present study refers to lichenoid granulomatous dermatitis (LGD) and lichenoid granulomatous st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::705e540d30bc37316385a138449fc6e4
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3100297
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3100297
Autor:
Tryfonopoulos, D., Walsh, S., Collins, D.M., Flanagan, L., Quinn, C., Corkery, B., McDermott, E.W., Evoy, D., Pierce, A., O’Donovan, N. *, Crown, J., Duffy, M.J.
Publikováno v:
In Annals of Oncology October 2011 22(10):2234-2240
Pulmonary embolism (PE), along with deep vein thrombosis, are collectively known as venous thromboembo- lism (VTE). Predisposing factors for PE include post-operative conditions, pregnancy, cancer and an advanced age; of note, a number of genetic mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::2c2b35b0575db3b468bb63f8ecac915b
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3220182
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3220182
Purpose: Gastric cancer is the fifth most common neoplasm worldwide with high rates of mortality. Afatinib, a low molecular, irreversible potent inhibitor of ErbB trans-membrane receptor family, has shown promising results according to preclinical an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::68a1550504207ba7944b9b6bc98f4f70
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3120203
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3120203
Background We evaluated real-world clinical outcomes and toxicity data and assessed treatment-related costs in patients with advanced breast cancer who received treatment with cyclin-dependent kinase inhibitors (CDKi). Patients and methods We conduct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::5b59cb3345110abec116bb9e4efc4068
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078145
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078145
Background: Cabazitaxel is a novel taxane that might be active in breast cancer resistant to first-generation taxanes. Methods: The purpose of the current multicentre phase II trial was to evaluate the activity and safety of cabazitaxel, as second-li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::73aa05f04a6b1bd5689b4018e2543062
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078780
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078780
Background Gene panel testing has become the norm for assessing breast cancer (BC) susceptibility, but actual cancer risks conferred by genes included in panels are not established. Contrarily, deciphering the missing hereditability on BC, through id
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::ed55606a9f933b009488e05c955bf952
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077744
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077744
Introduction: BRCA1/BRCA2 mutation carriers indefinitely comprise a distinct group of patients with breast cancer (BC), with their tumors displaying specific pathologic characteristics. Although these connections are known, they are not fully elucida
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::f6e2ff2e41ba33d91835360956f03230
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078379
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078379
Autor:
Ioannou, S., Zouki, D., Kardara, V., Exarchos, K., Arvanitou, E., Gkikas, K., Stavrou, N., Koronakis, G., Tourkantonis, I., Grivas, A., Kourakos, P., Gouveris, P., Kypreos, D., Korkolis, D., Tryfonopoulos, D., Demiri, S., Papaxoinis, G.
Publikováno v:
In Annals of Oncology June 2023 34 Supplement 1:S98-S98